Yıl: 2017 Cilt: 41 Sayı: 6 Sayfa Aralığı: 901 - 918 Metin Dili: İngilizce

Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors

Öz:
Histone deacetylases (HDACs) are enzymes that act on histone proteins to remove the acetyl group and thereby regulate the chromatin state. HDACs act not only on histone protein but also nonhistone proteins that are key players in cellular processes such as the cell cycle, signal transduction, apoptosis, and more. "Classical" HDACs have been shown to be promising targets for anticancer drug design and development. However, the selectivity of HDAC inhibitors for HDAC isoforms remains the motivation of current research in this field. Here, we explored Class I HDACs and HDAC6 by sequence alignment and structural superimposition, catalytic channel extraction, and identification of critical residues involved in HDAC catalysis. Based on the general pharmacophore features of known HDAC inhibitors, we developed a library of compounds by scaffold hopping on a fragment hit identified via structure-based virtual screening of the molecular fragment library retrieved from the Otava database. Molecular docking assay revealed five of these compounds to have increased potency and selectivity for HDACs 1 and 2. Furthermore, their predicted absorption, distribution, metabolism, elimination, and toxicity (ADMET) properties were consistent with those of drug-like compounds. With further modeling-based and experiment
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Akamatsu M, Fujikawa M, Nakao K, Shimizu R (2009). In silico prediction of human oral absorption based on QSAR analyses of PAMPA permeability. Chem Biodivers 6: 1845-1866.
  • Bannister AJ, Kouzarides T (2011). Regulation of chromatin by histone modifications. Cell Res 21: 381-395.
  • Bazzaro M, Lin Z, Santillan A, Lee MK, Wang MC, Chan KC, Bristow RE, Mazitschek R, Bradner J, Roden RBS (2008).Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res 14: 7340-7347.
  • Böhm HJ, Flohr A, Stahl M (2004). Scaffold hopping. Drug Discov 1: 217-224.
  • Bolden JE, Peart MJ, Johnstone RW (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769- 784.
  • Boumber Y, Younes A, Garcia-Manero G (2011). Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opin Investig Drugs 20: 823-829.
  • Bracker TU, Sommer A, Fichtner I, Faus H, Haendler B, Hess- Stumpp H (2009). Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models. Int J Oncol 35: 909-920.
  • Cacan E, Ali MW, Boyd NH, Hooks SB, Greer SF (2014). Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance. PLoS One 9: 87455.
  • Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, Lee PW, Tang Y (2012). AdmetSAR: A comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model 52: 3099-3105
  • Cosenza M, Civallero M, Pozzi S, Marcheselli L, Sacchi S (2014). Preclinical screening of the HDAC6 inhibitor rocilinostat (ACY-1215) combined with bendamustine in lymphoma cell lines. Blood 124: 3124.
  • de Magalhães CS, Barbosa HJC, Dardenne LE (2004). A genetic algorithm for the ligand-protein docking problem. Genet Mol Biol 27: 605-610.
  • Di L, Kerns EH (2008). Drug-Like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization. 1st ed. Burlington, MA, USA: Academic Press.
  • Dong CY, Jiang YJ, Zhou JW, Yu, Sen YQ, You QD (2008). Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. J Mol Graph Model 26: 1160-1168.
  • Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188-193.
  • Fischle W, Kiermer V, Dequiedt F, Verdin E (2001). The emerging role of class II histone deacetylases. Biochem Cell Biol 79: 337-348.
  • Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Lu AH, Zhou NZ, Robert MF, Gillespie J et al. (2008). MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7: 759-768.
  • Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K et al. (2005). Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391-400.
  • Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH Jr, Rousseau C, Kalita A et al. (2008). Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112: 981- 989.
  • Ghasemi J, Saaidpour S (2007). QSPR prediction of aqueous solubility of drug-like organic compounds. Chem Pharm Bull 55: 669- 674.
  • Godman CA, Joshi R, Tierney BR, Greenspan E, Rasmussen TP, Wang H, Shin D, Rosenberg DW, Giardina C (2008). HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling. Cancer Biol Ther 7: 1570-1580.
  • Gregoretti IV, Lee YM, Goodson HV (2004). Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338: 17-31.
  • Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL (2003). Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. P Natl Acad Sci USA 100: 4389-4394.
  • Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN (2004). Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59: 177-189.
  • Huang YX, Zhao J, Song QH, Zheng LH, Fan C, Liu TT, Bao YL, Sun LG, Zhang LB, Li YX (2016). Virtual screening and experimental validation of novel histone deacetylase inhibitors. BMC Pharmacol Toxicol 17: 32.
  • Khorasanizadeh S (2004). The nucleosome: from genomic organization to genomic regulation. Cell 116: 259-272.
  • Kim HJ, Bae SC (2011). Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 3: 166-179.
  • Kouzarides T (2007). Chromatin modifications and their function. Cell 128: 693-705.
  • Langdon SR, Ertl P, Brown N (2010). Bioisosteric replacement and scaffold hopping in lead generation and optimization. Mol Inform 29: 366-385.
  • Lauffer BE, Mintzer R, Fong R, Mukund S, Tam C, Zilberleyb I, Flicke B, Ritscher A, Fedorowicz G, Vallero R et al. (2013). Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J Biol Chem 288: 26926-26943.
  • Li B, Carey M, Workman JL (2007). The role of chromatin during transcription. Cell 128: 707-719.
  • Lipinski CA (2004). Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 1: 337-341.
  • Liu XH, Song HY, Zhang JX, Han BC, Wei XN, Ma XH, Cui WK, Chen YZ (2010). Identifying novel type ZBGs and nonhydroxamate HDAC inhibitors through a SVM based virtual screening approach. Mol Inform 29: 407-420.
  • MacKerell AD, Banavali NK (2000). All-atom empirical force field for nucleic acids: II. Application to molecular dynamics simulations of DNA and RNA in solution. J Comp Chem 21: 105-120.
  • McConkey DJ, White M, Yan W (2012). HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer. Adv Cancer Res 116: 131-163.
  • Millard CJ, Watson PJ, Celardo I, Gordiyenko Y, Cowley SM, Robinson CV, Fairall L, Schwabe JW (2013). Class I HDACs share a common mechanism of regulation by inositol phosphates. Mol Cell 51: 57-67.
  • Mottamal M, Zheng S, Huang T, Wang G (2015). Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 20: 3898-3941.
  • Nair SB, Teli MK, Pradeep H, Rajanikant GK (2012). Computational identification of novel histone deacetylase inhibitors by docking based QSAR. Comput Biol Med 42: 697-705.
  • Newbold A, Matthews GM, Bots M, Cluse LA, Clarke CJP, Banks KM, Cullinane C, Bolden JE, Christiansen AJ, Dickins RA et al. (2013). Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities. Mol Cancer Ther 12: 2709- 2721.
  • Nordqvist A, Nilsson J, Lindmark T, Eriksson A, Garberg P, Kihlén M (2004). A general model for prediction of Caco-2 cell permeability. QSAR Comb Sci 23: 303-310.
  • Noureen N, Kalsoom S, Rashid H (2010). Ligand based pharmacophore modelling of anticancer histone deacetylase inhibitors. Afr J Biotechnol 9: 3923-3931.
  • Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, Deimling AV et al. (2009). Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 15: 91-99.
  • Ouyang H, Ali YO, Ravichandran M, Dong A, Qiu W, MacKenzie F, Dhe-Paganon S, Arrowsmith CH, Zhai RG (2012). Protein aggregates are recruited to aggresome by histone deacetylase 6 via unanchored ubiquitin C termini. J Biol Chem 287: 2317- 2327.
  • Owens J, Lipinski CA (2003). Chris Lipinski discusses life and chemistry after the Rule of Five. Drug Discov Today 8: 12-16.
  • Paixão P, Gouveia LF, Morais JAG (2010). Prediction of the in vitro permeability determined in Caco-2 cells by using artificial neural networks. Eur J Pharm Sci 41: 107-117.
  • Park H, Kim S, Kim YE, Lim SJ (2010). A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups. ChemMedChem 5: 591-597.
  • Park SY, Jun JA, Jeong KJ, Heo HJ, Sohn JS, Lee HY, Park CG, Kang J (2011). Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep 25: 1677-1681.
  • Peng L, Seto E (2011). Deacetylation of nonhistone proteins by HDACs and the implications in cancer. Handbook of Experimental Pharmacology 206: 39-56.
  • Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA (2011). Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 106: 77-84.
  • Ponce YM, Perez MAC, Zaldivar VR, Sanz MB, Mota DS, Torrens F (2005). Prediction of intestinal epithelial transport of drug in (Caco-2) cell culture from molecular structure using in silico approaches during early drug discovery. J Mol Des 4: 124-150.
  • Prakash S, Foster BJ, Meyer M, Wozniak A, Heilbrun LK, Flaherty L, Zlupski M, Radulovic L, Valdivieso M, LoRusso PM (2001). Chronic oral administration of CI-994: a phase 1 study. Invest New Drugs 19: 1-11.
  • Rajendran P, Delage B, Dashwood WM, Yu T, Wuth B, Williams DE, Ho E, Dashwood RH (2011). Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly. Mol Cancer 10: 68.
  • Richmond TJ, Davey CA (2003). The structure of DNA in the nucleosome core. Nature 423: 145-150.
  • Ridder L, Wang H, de Vlieg J, Wagener M (2011). Revisiting the rule of five on the basis of pharmacokinetic data from rat. ChemMedChem 6: 1967-1970.
  • Roth SY, Denu JM, Allis D (2001). Histone acetyltransferases. Annu Rev Biochem 70: 81-120.
  • Sakuma T, Uzawa K, Onda T, Shiiba M, Yokoe H, Shibahara T, Tanzawa H (2006). Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol 29: 117-124.
  • Schüler S, Fritsche P, Diersch S, Arlt A, Schmid RM, Saur D, Schneider G (2010). HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol Cancer 9: 80.
  • Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang SW (2010). Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther 10: 935-954.
  • Singh KP, Gupta S, Basant N (2015). In silico prediction of cellular permeability of diverse chemicals using qualitative and quantitative SAR modeling approaches. Chemometr Intell Lab 140: 61-72.
  • Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, Luong C, Arvai A, Buggy JJ, Chi E (2004). Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12: 1325-1334.
  • Spurling CC, Godman CA, Noonan EJ, Rasmussen TP, Rosenberg DW, Giardina C (2008). HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol Carcinog 47: 137-147.
  • Sundarapandian T, Shalini J, Sugunadevi S, Woo LK (2010). Docking- enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery. J Mol Graph Model 29: 382-395.
  • Thangapandian S, John S, Sakkiah S, Lee KW (2010). Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design. Eur J Med Chem 45: 4409-4417.
  • Van Breemen RB, Li Y (2005). Caco-2 cell permeability assays to measure drug absorption. Expert Opin Drug Metab Toxico 1: 175-185.
  • Verdin E, Dequiedt F, Kasler HG (2003). Class II histone deacetylases: versatile regulators. Trends Genet 19: 286-293.
  • Volpe DA (2011). Drug-permeability and transporter assays in Caco- 2 and MDCK cell lines. Future Med Chem 3: 2063-2077.
  • Volpe DA, Faustino PJ, Ciavarella AB, Asafu-Adjaye EB, Ellison CD, Yu LX, Hussain AS (2007). Classification of drug permeability with a Caco-2 cell monolayer assay. Clin Res Reg Affairs 24: 39-47.
  • Wang T, Sepulveda M, Gonzales P, Gately S (2013). Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents. Bioorg Med Chem Lett 23: 4790-4793.
  • Watson PJ, Fairall L, Santos GM, Schwabe JWR (2012). Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. Nature 481: 335-340.
  • Weiner SJ, Kollman PA, Case DA, Singh UC, Ghio C, Alagona G, Profeta S, Weinerl P (1984). A new force field for molecular mechanical simulation of nucleic acids and proteins. J Am Chem Soc 106: 765-784.
  • Wilson AJ, Byun DS, Popova N, Murray LB, L’Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM (2006). Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281: 13548- 13558.
  • Xiang Y, Hou Z, Zhang Z (2012). Pharmacophore and QSAR studies to design novel histone deacetylase 2 inhibitors. Chem Biol Drug Des. 79: 760-70.
  • Xie HJ, Noh JH, Kim JK, Jung KH, Eun JW, Bae HJ, Kim MG, Chang YG, Lee JY, Park H et al. (2012). HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. PLoS One 7: 34265.
  • Yang XJ, Grégoire S (2005). Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol 25: 2873-2884.
  • Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S, Iwase H (2005). Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treat 94: 11-16.
  • Zentner GE, Henikoff S (2013). Regulation of nucleosome dynamics by histone modifications. Nat Struct Mol Biol 20: 259-266.
APA AUBA B, YELEKÇİ K (2017). Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors. Turkish Journal of Biology, 41(6), 901 - 918.
Chicago AUBA Budullahi İbrahim,YELEKÇİ KEMAL Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors. Turkish Journal of Biology 41, no.6 (2017): 901 - 918.
MLA AUBA Budullahi İbrahim,YELEKÇİ KEMAL Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors. Turkish Journal of Biology, vol.41, no.6, 2017, ss.901 - 918.
AMA AUBA B,YELEKÇİ K Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors. Turkish Journal of Biology. 2017; 41(6): 901 - 918.
Vancouver AUBA B,YELEKÇİ K Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors. Turkish Journal of Biology. 2017; 41(6): 901 - 918.
IEEE AUBA B,YELEKÇİ K "Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors." Turkish Journal of Biology, 41, ss.901 - 918, 2017.
ISNAD AUBA, Budullahi İbrahim - YELEKÇİ, KEMAL. "Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors". Turkish Journal of Biology 41/6 (2017), 901-918.